Agilent Reports Strong Q3 Earnings, Surpassing Expectations with Year-over-Year Revenue Growth and Rising Stock Prices
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 28 2025
0mins
Should l Buy PAHC?
Source: NASDAQ.COM
Earnings Report: Agilent Technologies reported Q3 fiscal 2025 earnings of $1.37 per share, exceeding estimates by 0.74%, with revenues of $1.74 billion also surpassing expectations by 4.6%.
Segment Performance: The company operates through three segments: Life Sciences and Diagnostics (LDG), Agilent CrossLab (ACG), and Applied Markets (AMG), with LDG generating the highest revenue at $670 million.
Financial Metrics: Gross margins declined across all segments, while R&D expenses decreased slightly, and SG&A expenses rose marginally. The overall non-GAAP operating margin contracted to 25.1%.
Future Outlook: For Q4 fiscal 2025, Agilent anticipates revenues between $1.822-$1.842 billion and expects full-year revenues of $6.91-$6.93 billion, indicating growth projections for both periods.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PAHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PAHC
Wall Street analysts forecast PAHC stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 51.265
Low
45.00
Averages
47.50
High
50.00
Current: 51.265
Low
45.00
Averages
47.50
High
50.00
About PAHC
Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amazon's Huge Capital Spending Leads to Futures Losses and Bitcoin Bounce
- Market Volatility: Futures markets pared losses after the stock market broke key levels, indicating investor concerns about future economic prospects, which could lead to short-term market instability.
- Amazon's Capital Spending: Amazon's stock fell due to significant capital expenditures, reflecting the company's aggressive strategy in expansion and infrastructure investment, which may impact its short-term profitability.
- Bitcoin Bounce: Despite overall market pressure, Bitcoin saw a slight bounce, indicating a demand for digital assets as a safe haven in uncertain market conditions, potentially attracting more investor interest.
- Investor Sentiment: The market's strong reaction to Amazon's spending may lead investors to reassess the risk and return of tech stocks, influencing overall investment strategies.
See More
Stock Market Plummets Amid Amazon Earnings Miss
- Market Decline: The stock market experienced a significant sell-off on Thursday, with major indices declining broadly, reflecting investor concerns about the economic outlook amid high inflation and rising interest rates, which have dampened market confidence.
- Bitcoin Crash: Bitcoin prices fell sharply, driven by a bearish market sentiment as investors rushed to sell off crypto assets, likely due to concerns over increased regulation in the crypto market and a general rise in risk aversion.
- Amazon Earnings Miss: Amazon's stock price dropped following its earnings report, primarily due to concerns over its massive capital spending plans, which raised investor apprehensions about future profitability, highlighting the tension between expansion and earnings.
- Capital Expenditure Impact: While Amazon's capital expenditure plans aim to drive long-term growth, they may negatively affect cash flow and shareholder returns in the short term, leading to lowered market expectations for its future performance.
See More
Stock Market Plummets as Amazon Reports Disappointing Earnings
- Market Decline: The stock market experienced a significant sell-off on Thursday, with major indices declining broadly, reflecting investor concerns about the economic outlook, which may dampen market confidence and influence short-term investment decisions.
- Bitcoin Crash: Bitcoin prices fell sharply, contributing to a gloomy market sentiment, as investor confidence in cryptocurrencies wanes, potentially leading to further capital outflows from this asset class and affecting the stock performance of related companies.
- Amazon's Disappointing Earnings: Amazon's stock dropped following its earnings report, primarily due to concerns over its massive capital spending plans, which may prompt a reassessment of its long-term growth potential by the market.
- Impact of Capital Expenditure: While Amazon's capital expenditure plans aim to expand its business, they may exert pressure on cash flow in the short term, thereby affecting its stock performance and investor confidence.
See More
Align Technology Reports Strong Q4 Earnings Beat
- Earnings Beat: Align Technology reported Q4 earnings of $3.29 per share, surpassing analyst expectations of $2.97, indicating a significant improvement in profitability and boosting market confidence in future growth.
- Sales Growth: The company achieved quarterly sales of $1.047 billion, exceeding the consensus estimate of $1.033 billion, demonstrating robust performance amid strong market demand.
- Stock Surge: Align's shares jumped 10.4% in pre-market trading to $178.13, reflecting a positive investor reaction to the financial results, which may attract more investor interest.
- Increased Market Confidence: This earnings beat not only enhances Align's market image but also potentially supports its future investment and expansion plans, further solidifying its leadership position in the industry.
See More
Phibro Animal Health to Announce Q2 Financial Results on February 4, 2026
- Earnings Announcement: Phibro Animal Health Corporation is set to release its second-quarter financial results on February 4, 2026, after market close, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: Management will host a conference call on February 5, 2026, at 9:00 AM Eastern Time to provide insights into the financial results, aiming to bolster investor confidence in the company's future prospects.
- Participation Information: Interested parties can join the call by dialing +1 (888) 330-2022 for U.S. and Canada or +1 (365) 977-0051 for international callers, ensuring broad dissemination of information.
- Webcast Replay Availability: A replay of the webcast will be available approximately two hours after the live event, allowing investors who could not attend in real-time to access key information, further enhancing engagement between the company and its investors.
See More
Insulet's Omnipod 5 Platform Achieves Over $200 Million in International Revenue
- Market Share Growth: Insulet's Omnipod 5 platform achieved over $200 million in international revenue for the first time in Q3 2025, driven by rapid product adoption and increasing market demand, significantly enhancing the company's competitive position.
- Surge in U.S. Revenue: U.S. Omnipod revenues grew by 25.6% year-over-year, exceeding the high end of the company's guidance, indicating sustained strong demand for Omnipod 5 among both Type 1 and Type 2 diabetes patients, further expanding the company's market share.
- Strong Financial Health: As of Q3 2025, Insulet reported cash and cash equivalents of $757.4 million with current debt of $80 million, showcasing robust financial stability amid economic uncertainty, which supports future expansion and investment.
- Ongoing Strategic Investments: Insulet is increasing investments in platform innovation, including sensor integrations with Dexcom and Abbott, which are expected to further enhance its technological advantage and drive growth in global markets.
See More
Amazon's Huge Capital Spending Leads to Futures Losses and Bitcoin Bounce
- Market Volatility: Futures markets pared losses after the stock market broke key levels, indicating investor concerns about future economic prospects, which could lead to short-term market instability.
- Amazon's Capital Spending: Amazon's stock fell due to significant capital expenditures, reflecting the company's aggressive strategy in expansion and infrastructure investment, which may impact its short-term profitability.
- Bitcoin Bounce: Despite overall market pressure, Bitcoin saw a slight bounce, indicating a demand for digital assets as a safe haven in uncertain market conditions, potentially attracting more investor interest.
- Investor Sentiment: The market's strong reaction to Amazon's spending may lead investors to reassess the risk and return of tech stocks, influencing overall investment strategies.
See More
Stock Market Plummets Amid Amazon Earnings Miss
- Market Decline: The stock market experienced a significant sell-off on Thursday, with major indices declining broadly, reflecting investor concerns about the economic outlook amid high inflation and rising interest rates, which have dampened market confidence.
- Bitcoin Crash: Bitcoin prices fell sharply, driven by a bearish market sentiment as investors rushed to sell off crypto assets, likely due to concerns over increased regulation in the crypto market and a general rise in risk aversion.
- Amazon Earnings Miss: Amazon's stock price dropped following its earnings report, primarily due to concerns over its massive capital spending plans, which raised investor apprehensions about future profitability, highlighting the tension between expansion and earnings.
- Capital Expenditure Impact: While Amazon's capital expenditure plans aim to drive long-term growth, they may negatively affect cash flow and shareholder returns in the short term, leading to lowered market expectations for its future performance.
See More
Stock Market Plummets as Amazon Reports Disappointing Earnings
- Market Decline: The stock market experienced a significant sell-off on Thursday, with major indices declining broadly, reflecting investor concerns about the economic outlook, which may dampen market confidence and influence short-term investment decisions.
- Bitcoin Crash: Bitcoin prices fell sharply, contributing to a gloomy market sentiment, as investor confidence in cryptocurrencies wanes, potentially leading to further capital outflows from this asset class and affecting the stock performance of related companies.
- Amazon's Disappointing Earnings: Amazon's stock dropped following its earnings report, primarily due to concerns over its massive capital spending plans, which may prompt a reassessment of its long-term growth potential by the market.
- Impact of Capital Expenditure: While Amazon's capital expenditure plans aim to expand its business, they may exert pressure on cash flow in the short term, thereby affecting its stock performance and investor confidence.
See More
Align Technology Reports Strong Q4 Earnings Beat
- Earnings Beat: Align Technology reported Q4 earnings of $3.29 per share, surpassing analyst expectations of $2.97, indicating a significant improvement in profitability and boosting market confidence in future growth.
- Sales Growth: The company achieved quarterly sales of $1.047 billion, exceeding the consensus estimate of $1.033 billion, demonstrating robust performance amid strong market demand.
- Stock Surge: Align's shares jumped 10.4% in pre-market trading to $178.13, reflecting a positive investor reaction to the financial results, which may attract more investor interest.
- Increased Market Confidence: This earnings beat not only enhances Align's market image but also potentially supports its future investment and expansion plans, further solidifying its leadership position in the industry.
See More
Phibro Animal Health to Announce Q2 Financial Results on February 4, 2026
- Earnings Announcement: Phibro Animal Health Corporation is set to release its second-quarter financial results on February 4, 2026, after market close, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: Management will host a conference call on February 5, 2026, at 9:00 AM Eastern Time to provide insights into the financial results, aiming to bolster investor confidence in the company's future prospects.
- Participation Information: Interested parties can join the call by dialing +1 (888) 330-2022 for U.S. and Canada or +1 (365) 977-0051 for international callers, ensuring broad dissemination of information.
- Webcast Replay Availability: A replay of the webcast will be available approximately two hours after the live event, allowing investors who could not attend in real-time to access key information, further enhancing engagement between the company and its investors.
See More
Insulet's Omnipod 5 Platform Achieves Over $200 Million in International Revenue
- Market Share Growth: Insulet's Omnipod 5 platform achieved over $200 million in international revenue for the first time in Q3 2025, driven by rapid product adoption and increasing market demand, significantly enhancing the company's competitive position.
- Surge in U.S. Revenue: U.S. Omnipod revenues grew by 25.6% year-over-year, exceeding the high end of the company's guidance, indicating sustained strong demand for Omnipod 5 among both Type 1 and Type 2 diabetes patients, further expanding the company's market share.
- Strong Financial Health: As of Q3 2025, Insulet reported cash and cash equivalents of $757.4 million with current debt of $80 million, showcasing robust financial stability amid economic uncertainty, which supports future expansion and investment.
- Ongoing Strategic Investments: Insulet is increasing investments in platform innovation, including sensor integrations with Dexcom and Abbott, which are expected to further enhance its technological advantage and drive growth in global markets.
See More
